Postpartum Hemorrhage
Postpartum Hemorrhage is the leading cause of maternal death globally, and accounts for 100% of emergency, unplanned postpartum hysterectomies.
The US leads developed countries in maternal mortality. There is a noted disproportionate number of women of color affected by issues related to childbearing.
“Catastrophic postpartum hemorrhage typically occurs without warning. The severe cases quickly become life threatening. Currently, obstetrical care units lack an effective, fast acting, non-surgical solution that directly treats the root cause.
Avana Health is developing a treatment to address this gap in obstetric care. Avana Health’s approach is intended to complement standard-of-care pharmacologic treatments and may eliminate the need for most additional device and surgical interventions.”
Avana’s treatment system functions as a treatment for postpartum hemorrhage.
The treatment system, a drug and device kit, is intended to complement standard-of-care pharmacologic treatments and may eliminate the need for most additional device and surgical interventions.
Avana’s treatment system provides a faster alternative to current interventions
DRUG
Has an anticipated effect of under 3 minutes
Can be administered outside of a hospital environment.
The drug’s mechanism of action provides rapid, local cessation of blood flow
Does not require refrigerated storage
DEVICE
Requires minimal training for providers
Functions to create a water-tight seal and deliver optimal pressure of drug (critical for efficacy)
Single-use and sterile
Built-in function to measure / collect blood (i.e., quantitative blood loss)
It is imperative we develop better treatment alternatives.
PPH trends are disturbing. Incidence of PPH is increasing, and this shift is exacerbated by health inequities and rising comorbidities. Current solutions present challenges in low resource settings like rural regions and/or low and middle-income countries (LMICs).
We need better treatment options. World Health Organization reported two clinical studies “unexpectedly show unfavorable outcomes” for the current treatment using balloon tamponades.
To ensure Avana’s treatment reaches as many patients as possible, we will seek approval from a stringent national regulatory authority (NRA) and plan to pursue expedited regulatory approval.
The US leads developed countries in maternal mortality, disproportionately affecting women of color.
Sources: (1) Commonwealth Fund - 2018 Maternal Mortality and Maternity Care in the United States Compared to 10 Other Developed Countries. (2) CDC (cited on Bloomberg)
PPH is a leading cause of maternal mortality and developing countries tragically outpace the US in maternal deaths.
Our vision is to become a standard of care for treating postpartum hemorrhage.
Interested in learning about our work? Please fill out the form below, and we'll be happy to tell you more.